MI
ACRS icon

Motiv8 Investments’s Aclaris Therapeutics ACRS Stock Holding History

Motiv8 Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$3 Buy
+1,000
New +$2.53K ﹤0.01% 649

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Motiv8 Investments's ACRS Position: Q4 2025 in Review

Motiv8 Investments opened a new position in Aclaris Therapeutics (ACRS) in Q4 2025: 1,000 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #649 among its holdings.

122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Motiv8 Investments held 1,000 shares of Aclaris Therapeutics worth $3 as of Q4 2025.
  • Aclaris Therapeutics was a new Motiv8 Investments position in Q4 2025.
  • Aclaris Therapeutics made up ﹤0.01% of Motiv8 Investments's portfolio in Q4 2025, its #649 holding.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Motiv8 Investments's 13F filing for Q4 2025, filed 13 Feb 2026.